Sustained Low-Dose Treatment with the Histone Deacetylase Inhibitor LBH589 Induces Terminal Differentiation of Osteosarcoma Cells

Histone deacetylase inhibitors (HDACi) were identified nearly four decades ago based on their ability to induce cellular differentiation. However, the clinical development of these compounds as cancer therapies has focused on their capacity to induce apoptosis in hematologic and lymphoid malignancie...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Cain, Jason E., McCaw, Andrew, Jayasekara, W. Samantha N., Rossello, Fernando J., Marini, Kieren D., Irving, Aaron T., Kansara, Maya, Thomas, David M., Ashley, David M., Watkins, D. Neil
Formato: Artigo
Idioma:Inglês
Publicado em: Hindawi Publishing Corporation 2013
Assuntos:
Research Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3603321/
https://ncbi.nlm.nih.gov/pubmed/23533324
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1155/2013/608964
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados